当前位置: X-MOL 学术Prostate › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience
The Prostate ( IF 2.6 ) Pub Date : 2021-07-12 , DOI: 10.1002/pros.24189
Christopher E Wee 1 , Brian A Costello 1 , Jacob J Orme 1 , J Fernando Quevedo 1 , Lance C Pagliaro 1
Affiliation  

Chemotherapy in combination with immunotherapy has a proven survival benefit compared to chemotherapy alone in extensive stage small cell lung cancer (SCLC) and is the new standard of care. Since extrapulmonary small cell carcinomas (SCCs) are less common, treatment paradigms are reasonably extrapolated from SCLC regimens. We examined our institution's experience utilizing the combination of chemotherapy and immunotherapy (as used in SCLC) for SCC and neuroendocrine carcinoma of the prostate.

中文翻译:

Atezolizumab 化疗治疗前列腺小细胞癌或神经内分泌癌:单一机构的经验

与单独化疗相比,化疗联合免疫治疗在广泛期小细胞肺癌 (SCLC) 中具有经证实的生存益处,并且是新的护理标准。由于肺外小细胞癌 (SCC) 不太常见,因此可以从 SCLC 方案合理推断治疗范例。我们检查了我们机构使用化学疗法和免疫疗法(如在 SCLC 中使用的)组合治疗 SCC 和前列腺神经内分泌癌的经验。
更新日期:2021-08-13
down
wechat
bug